https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Aptinyx_Inc.Aptinyx Inc. - Revizia istoricului2026-04-09T19:05:37ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Aptinyx_Inc.&diff=406879&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Aptinyx Inc. listata cu simbolul US.APTX ==Descriere companie== Aptinyx Inc. (www.aptinyx.com) is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which...2024-09-18T13:38:27Z<p>Pagină nouă: Pagina dedicata companiei Aptinyx Inc. listata cu simbolul US.APTX ==Descriere companie== Aptinyx Inc. (www.aptinyx.com) is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Aptinyx Inc. listata cu simbolul US.APTX<br />
<br />
==Descriere companie==<br />
Aptinyx Inc. (www.aptinyx.com) is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which are focused on brain and nervous system functions. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and Lewy body dementia.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.APTX" /><br />
<br />
==Ultimele stiri despre Aptinyx Inc. (US.APTX)==<br />
<dynamicpagelist><br />
category=US.APTX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.APTX]][[Categorie:Stiri despre companii]]</div>Admin